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Abstract
Background: Onchocerciasis, caused by the parasitic nematode, Onchocerca volvulus afflicts some 37 million people
worldwide, and is the second leading infectious cause of blindness globally. The only currently recommended drug
for treatment of the disease, ivermectin, is only microfilaricidal and has serious adverse effects in individuals co-infected
with high loads of Loa loa microfilariae (mf), prompting the search for new and better drugs. Onchocerciasis drug
discovery studies have so far been based on in vivo models using Onchocerca species which are not the closest
to O. volvulus, and which may therefore, not adequately mimic the natural infection in humans. Therefore, this study was
carried out to develop a better drug screening model for onchocerciasis, based on the use of cow-derived O. ochengi, the
closest known relative of O. volvulus.
Methods: Mf of O. ochengi were injected subcutaneously at the nape of Syrian hamsters (Mesocricetus auratus)
and BALB/c mice. The skin, and especially the earlobes of the animals were examined for mf 15–31 days after
infection. For selected model validation, the hamsters were treated with ivermectin at 150 or 600 μg/kg body
weight and examined 30 days after infection for mf. For L. loa studies in hamsters, isolated mf were injected
intraperitoneally and animal organs were examined on day 26 for mf.
Results: The Syrian hamsters were found to be the more permissive to O. ochengi mf as fully viable mf were
recovered from them on day 30, compared to BALB/c mice where such mf were recovered on day 15, but not
30. However, both animals were not permissive to L. loa mf even by day 15. Interestingly, more than 50 % of
the total O. ochengi mf recovered were from the earlobes. The number of mf injected was directly proportional
to the number recovered. Ivermectin at both concentrations tested completely eliminated the O. ochengi mf
from the hamsters.
Conclusion: This study reveals the Syrian hamster as an appropriate small animal model for screening of novel
compounds against O. ochengi, the closest known relative of O. volvulus.
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Background
Onchocerciasis is a neglected tropical disease caused by
the filarial nematode, Onchocerca volvulus. It afflicts
some 37 million people globally, with 99 % of all the
cases living in sub-Saharan Africa [1]. Onchocerciasis
was estimated to account for 18.3 million disability-
adjusted life years (DALYs) in sub-Saharan Africa within
20 years [2]. It is the second leading infectious cause of
blindness worldwide [3]. The debilitating symptoms of
onchocerciasis are attributed to inflammatory reactions
to dead or dying O. volvulus microfilariae (mf) in the
skin and eyes [4, 5]. The mf of O. volvulus is the stage of
the parasite ingested during a blood meal on humans by
the black fly (of genus, Simulium), in which the mf
develop to the infective third stage larvae (L3), which
may be transmitted to another person when bitten by
the infected fly. Ivermectin, a microfilaricide is the only
recommended drug used in many onchocerciasis elimin-
ation programs to break the transmission cycle by killing
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the O. volvulus mf. This drug is unfortunately, only a
microfilaricide, and a major challenge with ivermectin
treatment is the fact that it also kills L. loa mf in blood,
a situation that often leads to severe adverse events
(encephalopathy and death) in individuals with high L.
loa mf load [6]. In addition, there is evidence of resist-
ance or low response rate of mf to ivermectin [7, 8],
emphasizing the need for new therapeutic options.
Efficacious small animal models in onchocerciasis for
in vivo screens and preclinical studies, capable of closely
mimicking the natural infection in humans are an ur-
gent, unmet need. Immunocompetent rodents are non-
permissive to natural infections of O. volvulus [9], but
experimentally injected O. lienalis mf have been shown
to survive in mice, especially in inbred CBA mice [10,
11]. The severe-combined immunodeficient (SCID) mice
have been exploited as a model for onchocerciasis and
are permissive to mf of O. lienalis [12]. The O. lienalis
mf mouse model has been validated with ivermectin and
other filaricides [10, 13]. However, O. ochengi in cattle is
the closest in phylogeny to O. volvulus [14] and many
onchocerciasis drug tests in vitro [15–18] and in natur-
ally infected cows [19–21] have been done based on O.
ochengi. However, the cow is too big, requires huge
quantities of drugs, thereby rendering it too expensive
for routine screening. Consequently, most funding bod-
ies are reticent in considering the cow as a useful model
for onchocerciasis. Both O. ochengi and O. volvulus are
transmitted by the same black fly vectors of genus,
Simulium. O. ochengi is confined to Africa and combines
many important features of the human infection with O.
volvulus [21]. O. ochengi also forms nodules with close
resemblance to those of O. volvulus [22], which can be
enumerated by palpation in situ or removed for analysis
during immunological or chemotherapeutic studies. More-
over, both parasites are equally susceptible to the filaricides,
ivermectin and suramin [23], and tetracyclines [24].
Molecular and biochemical comparisons reveal almost
identical antigenic and genomic profiles [25]. Given
that O. ochengi is readily available and can be obtained
at relatively low cost, it is currently regarded as a more
practical model in onchocerciasis drug screens [26].
However, no small laboratory animal has been reported
as a model to screen drugs on O. ochengi mf. This study
therefore, was aimed at developing and validating such
a model for onchocerciasis based on the use of O.
ochengi, and verifying the usefulness of the model for L.
loa mf counter screens.
Methods
Animals
Male and female Syrian hamsters (Mesocricetus auratus)
were purchased from Charles River (France) and flown to
Cameroon. These animals together with our home-bred
BALB/c mice were maintained in a conventional animal
house at the Biotechnology Unit of the University of Buea.
Animals were given food and water ad libidum. Animals
were aged 10–16 weeks at the time of use in the experi-
ments. This in vivo study was reported in accordance with
the ARRIVE Guidelines for reporting animal research.
L. loa patients and parasites
Due to the adverse effects observed during ivermectin
treatment of individuals co-infected with Onchocerca
and high loads of L. loa mf [6], we questioned if the
hamster and BALB/c mice were also permissive to L. loa
mf, thereby helping to find safer therapeutic options. L.
loa endemic areas of Edea and Mfou health districts of
the Littoral and Centre regions of Cameroon, respectively,
were targeted. Participants included those who con-
sented to participate in the study as L. loa parasite do-
nors after proper understanding of the intended study.
Individuals eligible for participation were adults of both
sexes, >21 years of age, in good health without any clinical
condition requiring long term treatment. Exclusion cri-
teria included an mf load of <5000/ml of blood and use of
anti-filarial therapy. A maximum of 20 ml of venous blood
was collected from eligible individuals at most 24 h before
L. loa mf isolation.
Extraction of mf
O. ochengi mf isolation
This was done following a method we described previously
[15], with slight modifications. Briefly, fresh pieces of
nodule-containing umbilical cattle skin were purchased
from a local slaughter house, washed repeatedly with tap
water until all dirt was removed, and rinsed with distilled
water. The skin was towel-dried and sterilized with 70 %
ethanol, allowed to dry in a laminar flow hood and firmly
attached to an autoclaved cylindrical-shaped wooden block.
Using sharp razor blades, criss-cross cuts were made
into the skin and submerged in ICM (incomplete cul-
ture medium: RPMI-1640 containing penicillin, strepto-
mycin and amphotericin B) for 4 h, after which, the
medium was centrifuged at 2500 rpm for 20 mins using
an Eppendorf 5810R centrifuge (Eppendorf, Germany)
to concentrate the mf. After viability check, the number
of mf were counted and adjusted to the required number
for experimental infection (5000–25,000) in 200–1000 μl
of ICM.
L. loa mf isolation
1 g of medium-grain Sephadex G-50 (Pharmacia Biotech,
Uppsala, Sweden) was weighed and allowed to swell over-
night in 20 ml of distilled water at 4 °C. Using 25 ml sero-
logical pipette as column, the swollen gel (after attaining
room temperature) was transferred and allowed to settle
to a bed volume of 11 ml. This column was equilibrated
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with 2 bed volumes of ICM, which was also the elution
buffer.
The number of L. loa mf per ml of blood was deter-
mined microscopically. Then 1 ml of the infected blood
was loaded on the column and allowed to just com-
pletely enter the gel bed before elution began. The red
coloration due to red blood cells was allowed to flow
through the gel completely before fraction collection
started. A total of 30 ml of eluate was collected for every
ml of blood loaded. Fractions were centrifuged at
2500 rpm for 20 mins using the Eppendorf 5810R cen-
trifuge, supernatants discarded, pellets re-suspended in
ICM, pooled and centrifuged as before. Sediments ob-
tained after the second centrifugation were re-suspended
in ICM and washed on 20 % percoll at 1000 rpm for 5
mins, thrice using the same centrifuge. After the third
wash, the procedure was repeated twice with 1x PBS
(phosphate buffered saline) in place of percoll. Sedi-
ments were finally re-suspended in a small volume of
ICM, and L. loa mf counted using a microscope.
Experimental infection with O. ochengi mf
Isolated mf were administered subcutaneously (sc) at
7250-44,100 per animal, in 1 ml of ICM using 29.5G
needles at the region behind the ears (nape). Mf were
100 % viable at time of injection.
Experimental infection with L. loa mf
Four hamsters were intraperitoneally infected, each with
30,000 L. loa mf at a viability of 98.97 % in 2 ml of PBS
using syringes with 29.5G needles. Animals were sacri-
ficed 26 days post-infection and examined for viable mf.
Drug administration
Ivermectin (Mectizan™; Sigma Aldrich, Germany) was
administered to two groups of hamsters (randomly
chosen after infection) per os, 3 days post-infection. One
group of 5 animals received ivermectin at 150 μg/kg body
weight and the other at 600 μg/kg body weight, while con-
trol animals received the vehicle (1 % DMSO) only.
Checking animals for presence of mf
O. ochengi mf
For O. ochengi mf recovery the skin, approximately
0.5 cm around the ears was completely shaved. Each ear
was carefully cut off, rinsed in distilled water, towel-
dried and sterilized with 70 % ethanol. Each pair of ears
was carefully chopped up into tiny bits and incubated in
5 ml of ICM at 37 °C for 4 h under sterile conditions.
During preliminary tests, the entire animal skin was
shaved and the skin of other body parts, including the fore
limbs, hind limbs, head, tail and trunk were chopped into
tiny pieces and also examined for mf. After incubation,
the total number of mf was obtained by spreading five
100 μl portions of ICM from each well on petri dishes and
observing microscopically to count the mf.
L. loa mf
For L. loa mf recovery, 200 μl of freshly collected blood
obtained by heart puncture of the animal post sedation,
were thinly spread on petri dishes in 20 μl portions and
observed microscopically.
After blood was collected, each animal was sacrificed
by cranial dislocation and its peritoneum washed with
50 ml PBS. After microscopic observation, the peritoneal
wash obtained was centrifuged at 400 × g for 15 mins,
supernatant discarded and pellets resuspended. All mf in
500 μl of the resuspended pellets were counted in 100 μl
sub-portions, for each animal. The animal organs, in-
cluding the heart, lungs, liver, spleen, kidneys, intestines,
stomach and trunk were removed and chopped into tiny
pieces and each set incubated in 7 ml of PBS (pH 7.4), at
37 °C for 1 h. After incubation as for the ear lobes, por-
tions of the chopped organs in buffer were observed
microscopically for the presence of L. loa mf.
Data analysis
Data were analysed using GraphPad Prism 5.0 software
and statistical analyses were performed using the Kruskal-
Wallis test and Dunn’s post-test. Data presented show
mean ± SEM. Data were considered to show statistical
significant difference when p < 0.05.
Results
The hamster is permissive to mf of O. ochengi, but not to
those of L. loa
To test if the Syrian hamster was permissive to O.
ochengi mf, three preliminary exploratory experiments
were done with different numbers of mf injected in each
animal (Table 1). Following exploratory testing of differ-
ent numbers of mf, the number was finally harmonized
to 25,000 mf/animal, unless otherwise stated. In these
studies, the hamsters were able to retain O. ochengi mf
in the skin detected on day 21 and 30 when the animals
were sacrificed. Most of the O. ochengi mf were found in
the extremities (ears, head, fore limbs and hind limbs)
and less or no mf in the tail. Interestingly, more than
50 % of the total O. ochengi mf recovered were from the
earlobes (Table 1). Preliminary experiments were also
done on BALB/c mice to verify their ability to host O.
ochengi mf for 30 days. BALB/c mice tolerated O.
ochengi mf injected into them for 15 days, but not
30 days, as no mf was recovered on day 30. None of the
animals analyzed showed any tissue or whole body path-
ology (Table 1). From these preliminary experiments, the
hamster was considered more permissive to O. ochengi
mf (day 30 data) and therefore, was used for the rest of
the study. In addition, since the earlobes had more than
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M 25,000 100 % 30 27 7 353 0 67 53 507 (2) 69.63 None
observed
BALB/c 1 M 25,000 100 % 15 120 20 390 20 610 180 1340 (5.36) 29.10 None
observed
BALB/c 2 M 25,000 100 % 30 0 0 0 0 0 0 0 (0) 0 None
observed
BALB/c 3 M 25,000 100 % 31 0 0 0 0 0 0 0 (0) 0 None
observed
BALB/c 4 M 25,000 100 % 30 0 0 0 0 0 0 0 (0) 0 None
observed
BALB/c 5 F 25,000 100 % 31 0 0 0 0 0 0 0 (0) 0 None
observed
Different numbers of O. ochengi mf isolated from cattle skin on different days were injected subcutaneously at the nape of different animal types and the animals were sacrificed on indicated days and analyzed














50 % of the total O. ochengi mf recovered, they were the
only sites analyzed for the rest of this study. Unfortu-
nately, after infecting 4 hamsters and 5 BALB/c mice, no
L. loa mf was recovered from any of the animals (results
not shown).
O. ochengi mf recovery reduces with time and is linearly
proportional to number administered
To characterize the O. ochengi mf hamster model, the
effect of time on mf recovery post-infection was
assessed. Twenty one days post-infection with 20,000
the mf, 1199 ± 158 mf were recovered from the earlobes,
representing 6.0 % of the total mf injected (Fig. 1). After
30 days, 773 ± 144 O. ochengi mf were recovered from
the earlobes, representing 3.9 % of the total mf injected.
The change in mf numbers from 1199 ± 158 to 773 ±
144 in the earlobes between day 21 and 30 respectively,
marks a 35.5 % drop.
Next, we assessed the effect of number of O. ochengi
mf injected on recovery. Hamsters were infected with
5000, 10,000 or 20,000 mf and their earlobes were ana-
lyzed on day 30. Interestingly, increasing the number of
mf injected resulted in a linear increase in the number
of mf recovered (Fig. 2). The percentage of mf recovered
from the earlobes on day 30 was 7–8 %, irrespective of
number of mf injected.
Ivermectin completely clears O. ochengi mf from hamsters
in model validation studies
Finally, to validate the suitability of this model, we used
the drug of choice ivermectin. Three days after infection
of animals with O. ochengi mf, 5 hamsters per group
were dosed orally with ivermectin at 150 or 600 μg/kg
body weight, or received the vehicle only. When animals
were sacrificed on day 30, all the control animals had O.
ochengi mf in the earlobes (Fig. 3). On the contrary, in
all the animals treated with ivermectin at 150 or 600 μg/kg
body weight, no O. ochengi mf was recovered. The control
and treated groups showed a statistical significant dif-
ference (p = 0.0013) after a Kruskal-Wallis test. Further
statistical analysis of each ivermectin-treated group ver-
sus the control group with Dunn’s post-test indicated










































Fig. 3 Ivermectin completely eliminates O. ochengi mf in hamsters.
7250 O. ochengi mf were injected sc at the nape per animal and
animals treated once with the drug by oral gavage on day 3 at 150
or 600 μg/kg body weight. Control animals were treated with the
vehicle (1 % DMSO). Animals were sacrificed on day 30 and analyzed


























Fig. 1 Population of O. ochengi in hamster decreases overtime. 20,000
O. ochengi mf were injected sub-cutaneously (sc) at the nape and
animals were sacrificed on day 21 and 30, and mf recovered from the

































Fig. 2 Recovery of O. ochengi mf in hamster is directly proportional
to number of mf injected. Different numbers of O. ochengi mf were
injected sc at the nape and animals were sacrificed on day 30 and
mf recovered from the earlobes and counted (n = 3/group)
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show that the Syrian hamster is a good model to test
drugs on O. ochengi mf.
Discussion
The present study was carried out to develop a small im-
munocompetent animal model for onchocerciasis drug
screens, based on the use of bovine-derived O. ochengi,
the closest known relative of O. volvulus. Previously devel-
oped onchocerciasis mf models have all been based on use
of mice experimentally infected with animal Onchocerca
species which are not the closest to O. volvulus. We found
for the first time that the Syrian hamster is a suitable
model for harboring O. ochengi mf for more than 30 days,
without any observable pathology. Although only 3 ham-
sters were used in preliminary studies (Table 1), the data
presented in Figs. 1, 2 and 3 involving different sets of
more of the animal all show that the hamster retained
mf until day 30, fortifying the claim that it is a permis-
sive host. The goal was to maintain O. ochengi mf for
30 days in the model, but we can say that the mf can
survive longer in the hamsters, given that hundreds of
mf were recovered on day 30. In our opinion, 30 days is
enough time to verify reduction in mf viability, not ne-
cessarily elimination, with drug testing. None of the an-
imals tested showed any pathology or signs of illness
due to the O. ochengi mf infection. The model would
enable preclinical drug discovery efforts in vivo to com-
plement already well-established in vitro assays. A
simple technique previously developed by our labora-
tory [15], permits the production of large quantities
(hundreds of thousands) of O. ochengi mf for the
screens, from an mf rich cattle skin obtainable from
local slaughterhouses.
BALB/c mice were able to retain O. ochengi mf for
15 days. However, on day 30, no mf was recovered from
all infected BALB/c mice. In contrast, all infected ham-
sters had many mf in almost every part of the skin, with
the same or even lower number of mf injected. These
observations show that the hamster is more tolerant to
O. ochengi mf than BALB/c mice on day 30, and is
therefore, a more suitable model for standard onchocer-
ciasis drug screens. The mechanism of mf clearance by
mice or other rodents is not known. From literature it is
clear that the immune response plays a critical role in
parasite survival in an immunocompetent host. That is
why immunocompromised and transgenic animals lack-
ing crucial cytokines like IL-4 and IL-5 have been
exploited to improve filariae survival in mice. But the
situation is not straightforward. For example, BALB/c
mice are known to be more Th2-biased [27, 28], produ-
cing cytokines such as IL-4 and IL-5 which have been
implicated in the clearing of filarial parasites from the
mammalian host [29–31]. However, some filaria para-
sites do well in Balb/c mice than in other strains of
mouse. But a fully immunocompetent host for drug
screens would be better at mimicking the complex situ-
ation in humans. Our observation that the fully immuno-
competent hamster is better than BALB/c mice in
harboring O. ochengi mf for longer periods, suggest that
attention should be paid to other small immunocompe-
tent rodents (other than mice), such as gerbils in devel-
oping onchocerciasis animal models. Interestingly,
other workers have shown that gerbils are permissive to
O. ochengi adult male worms [32]. The only O. ochengi
mouse model reported to date is the SCID mouse [32],
emphasizing the need to further explore the mouse
world for smaller O. ochengi-based models of onchocer-
ciasis. This mouse is also permissive to adult O. ochengi
male and female worms. However, its lack of an adaptive
immune system clearly undermines the possible assisting
role of an intact immune system in drug-mediated killing
of parasites.
Efforts to develop a L. loa and O. ochengi mf co-
infection model for drug screens were hindered by the
non-permissiveness of the hamster to L. loa mf. More
research to identify such a co-infection model would be
highly beneficial to the scientific community interested
in novel onchocerciasis drugs, and is currently one of
the main areas of interest in our laboratory. Counter
screening systems for verification of inactivity of new
drugs on L. loa mf in vivo may help later on in avoiding
or mitigating the adverse effects such as those that are
observed in onchocerciasis patients co-infected with L.
loa after ivermectin treatment [6].
As expected, the number of O. ochengi mf in the
hamsters drops with duration of infection. The mf re-
covery was also directly proportional to the number
administered. On day 30, the maximum recovery was
8 % which is close to the 10 % described in CBA mice
35 days after infection with O. lienalis [11]. The per-
centage of mf recovered varied between experiments,
and this could probably be attributed to genetic
differences between the outbred hamsters. The present
model was validated with ivermectin. A dose of 150 μg/kg
body weight eliminated all O. ochengi mf. Therefore,
ivermectin will be a good positive control for testing of
drugs in this model. This model can be used for drugs that
are active on both micro- and macrofilariae or to acquire
more data in the study of microfilaricides. It can also be
used as counter screen in situations where newly devel-
oped macrofilaricide is not expected to be active against
mf, to reduce adverse drug effects resulting from dying
mf. However, a major limitation of the model is that it
is yet to be tested or developed further to include
macrofilaricidal drug screens. Further work is on-going
to identify novel microfilaricides using the model and
to investigate the incorporation of adult worm screens
into it.
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Conclusions
This study has revealed that the Syrian hamster is a
model for O. ochengi mf, the closest relative of O. volvu-
lus. It also revealed that BALB/c mice are not permissive
to O. ochengi mf by day 30, although they were on day
15. This is the first small laboratory animal model de-
scribed for this species of mf and may serve as an im-
portant preclinical complement to in vitro and other in
vivo drug screens for onchocerciasis.
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